Distinguishing medullary carcinoma of the breast from high-grade hormone receptor-negative invasive ductal carcinoma: An immunohistochemical approach

Histopathology

Volumn 56, Issue 7, 2010, Pages 852-859

  Flucke, Uta ^a   Flucke, Maria Theresia ^a   Hoy, Ludwig ^b   Breuer, Elisabeth ^c   Goebbels, Rolf ^d   Rhiem, Kerstin ^e   Schmutzler, Rita ^e   Winzenried, Helene ^a   Braun, Michael ^a   Steiner, Susanne ^a   Buettner, Reinhard ^a   Gevensleben, Heidrun ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c RWTH AACHEN UNIVERSITY   (Germany)

^d Institute of Pathology   (Germany)

^e UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Breast cancer; Invasive ductal carcinoma; Luminal; Medullary carcinoma; Myoepithelial

Indexed keywords

CD56 ANTIGEN; CELL ADHESION MOLECULE; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; P CADHERIN; PROTEIN P53; PROTEIN P63; SMOOTH MUSCLE ACTIN; SYNDECAN 1; TRANSCRIPTION FACTOR AP 2; UVOMORULIN; VIMENTIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER STAGING; CELL ADHESION; CLINICAL FEATURE; COMPARATIVE STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MEDULLARY CARCINOMA; MYOEPITHELIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SMOOTH MUSCLE; BREAST TUMOR; DIFFERENTIAL DIAGNOSIS; FEMALE; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, MEDULLARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77953211478     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03555.x     Document Type: Article

References (40)

1. Anderson WF, Chu KC, Chang S et al. Comparison of age-specific incidence rate patterns for different histopathologic types of breast cancer. Cancer Epidemiol. Biomarkers Prev. 2004 13 1128 1135.
2. Bloom HJ, Richardson WW, Field JR. Host resistance and survival in carcinoma of breast: a study of 104 cases of medullary carcinoma in a series of 1411 cases of breast cancer followed for 20 years. BMJ 1970 3 181 188.
3. Pedersen L, Holck S, Schiodt T et al. Inter- and intraobserver variability in the histopathological diagnosis of medullary carcinoma of the breast, and its prognostic implications. Breast Cancer Res. Treat. 1989 14 91 99.
4. Rakha EA, Putti TC, Abd El-Rehim DM et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J. Pathol. 2006 208 495 506.
5. Moore OS Jr., Foote FW Jr. The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 1949 2 635 642.
6. Pedersen L, Holck S, Mouridsen HT et al. Prognostic comparison of three classifications for medullary carcinoma of the breast. Histopathology 1999 34 175 178.
7. Ridolfi RL, Rosen PP, Port A et al. Medullary carcinoma of the breast: a clinicopathologic study with ten year follow up. Cancer 1977 40 1365 1385.
8. Vincent-Salomon A, Gruel N, Lucchesi C et al. Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res. 2007 9 R24.
9. Gaffey MJ, Mills SE, Frierson HF et al. Medullary carcinoma of the breast: interobserver variability in histopathological diagnosis. Mod. Pathol. 1995 8 31 38.
10. Rigaud C, Theobald S, Noel P et al. Medullary carcinoma of the breast. A multicenter study of its diagnostic consistency. Arch. Pathol. Lab. Med. 1993 117 1005 1008.
11. Rapin V, Contesso G, Mouriesse H et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988 61 2503 2510.
12. Reinfuss M, Stelmach A, Mitus J et al. Typical medullary carcinoma of the breast: a clinical and pathological analysis of 52 cases. J. Surg. Oncol. 1995 60 89 94.
13. Jacquemier J, Padovani L, Rabayrol L et al. Typical medullary breast carcinomas have a basalmyoepithelial phenotype. J. Pathol. 2005 207 260 268.
14. Domagala W, Wozniak L, Lasota J et al. Vimentin is preferentially expressed in high-grade ductal and medullary, but not in lobular breast carcinomas. Am. J. Pathol. 1990 137 1299 1304.
15. Milde S, Gaedke J, v Wasielewski R et al. [Diagnosis and immunophenotype of medullary breast cancer]. Pathologe 2006 27 358 362.
16. Scawn R, Shousha S. Morphologic sprectrum of estrogen receptor-negative breast carcinoma. Arch. Pathol. Lab. Med. 2002 126 325 330.
17. Tot T. The cytokeratin profile of medullary carcinoma of the breast. Histopathology 2000 37 175 181.
18. Banerjee S, Reis-Filho JS, Ashley S et al. Basal like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 2006 59 729 735.
19. Kim MJ, Ro JY, Ahn SH et al. Clinicopathological significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2neu-overexpressing phenotypes. Hum. Pathol. 2006 37 1217 1226.
20. Matos I, Dufloth R, Alvarenga M et al. p63, cytokeratin 5, and P-cadherin: tree molecular markers to distinguish basal phenotype in breast carcinomas. Virchows Arch. 2005 447 688 694.
21. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000 406 747 752.
22. Santini D, Ceccarelli C, Taffurelli M et al. Differentiation pathways in primary invasive breast carcinoma as suggested by intermediate filament and biopathological marker expression. J. Pathol. 1996 179 386 391.
23. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001 98 10869 10874.
24. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003 100 8418 8423.
25. Sorlie T, Wang Y, Xiao C et al. Molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006 7 127.
26. Friedrichs N, Jäger R, Paggen E. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod. Pathol. 2005 18 431 438.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991 19 403 410.
28. Kahl P, Gullotti L, Heukamp LC et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 2006 66 11341 11347.
29. Pauls K, Schorle H, Jeske W et al. Spatial expression of germ cell markers during maturation of human fetal male gonads: an immunohistochemical study. Hum. Reprod. 2006 21 397 404.
30. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv. Anat. Pathol. 2007 14 358 373.
31. Lidang Jensen M, Kiaer H, Andersen J et al. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology 1997 30 523 532.
32. Bertucci F, Finetti P, Cervera N et al. Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res. 2006 66 4636 4644.
33. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006 19 264 271.
34. Bosher JM, Totty NF, Hsuan JJ et al. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996 13 1701.
35. McPherson LA, Weigel RJ. AP2alpha and AP2gamma: a comparison of binding site specificity and transactivation of the estrogen receptor promoter and single site promoter constructs. Nucleic Acids Res. 1999 27 4040.
36. Seshadri R, Raymond WA, Leong AS et al. Vimentin expression is not associated with poor prognosis. Int. J. Cancer 1996 67 353 356.
37. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001 61 (Suppl. 2 1 13.
38. Baba F, Swartz K, Van Buren R et al. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype. Breast Cancer Res. Treat. 2006 98 91 98.
39. Barbareschi M, Maisonneuve P, Aldovini D et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003 98 474 483.
40. Leivonen M, Lundin J, Nordling S et al. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004 67 11 18.